Entrada Therapeutics, Inc. (TRDA)

USD 17.1

(-7.32%)

Market Cap (In USD)

639.88 Million

Revenue (In USD)

129.01 Million

Net Income (In USD)

-6.68 Million

Avg. Volume

145.98 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
11.35-21.79
PE
-
EPS
-
Beta Value
-0.265
ISIN
US29384C1080
CUSIP
29384C108
CIK
1689375
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dipal Doshi
Employee Count
-
Website
https://www.entradatx.com
Ipo Date
2021-10-29
Details
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.